bibr 1017 bs
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2004 (NCT02184338)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Telomerase reverse transcriptaseINHIBITOR
TERT inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- bibr 1017 bs
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06184269 | Phase 1 | Dec 31, 2023 | Boryung Pharmaceutical Company |
| NCT05372380 | Phase 1 | May 9, 2022 | Boryung Pharmaceutical Company, Cha Medical University |
| NCT02184338 | Phase 1 | Aug 1, 2004 | Boehringer Ingelheim |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boryung Pharmaceutical Company | For profit | 2 | 2 | 1 | 2022 |
| Boehringer Ingelheim | For profit | 1 | 1 | 1 | 2004 |
| Cha Medical University | Academic/Hospital | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1